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Abstract 
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Mammalian cells mainly utilize two DNA repair pathways to repair double stranded 
breaks (DSB): homologous recombination (HR) and non-homologous end joining 
(NHEJ). While HR utilizes homologous DNA sequences as a template for repair, NHEJ 
processes and re-ligates the ends of the breaks. NHEJ is further sub-divided into a DNA-
PK-dependent canonical pathway, and alternative pathways, which are more mutagenic. 
These pathways are essential for cell survival after ionizing radiation, and thus have 
become important therapeutic targets for radiosensitization. Our group recently 
performed multiple high-throughput small molecule screens for novel DSB repair 
inhibitors. These studies identified numerous selective NHEJ and HR inhibitors, many of 
which are unknown compounds. Our group now seeks to evaluate the underlying 
mechanisms by which these compounds regulate DSB repair. To this end, we built an 
automated, high-throughput secondary assay platform to interrogate hits identified from 
primary screens. This includes an adherent cell, imaging cytometry platform to rapidly 
assay GFP- and RFP-based reporter cell lines in 96- and 384-well microplates, to assess 
DNA content and S-phase proliferation, as well as to perform miniaturized clonogenic 
survival assays. We then applied this platform to the hits from our primary screens. We 
identified two groups of compounds from our initial screens: A) novel HSP90 inhibitors 
 
 
and B) cardiac glycosides. Compounds from group A resembled known HSP90 
inhibitors, but demonstrated different effects on key DSB repair pathways. One agent 
from group A demonstrated radiosensitivity in vitro. Compounds from both groups 
inhibited NHEJ and HR and were remarkably non-toxic at the majority of doses tested. 
This is the first report to demonstrate that cardiac glycosides inhibit both major DNA 
repair pathways. These data suggest a novel collection of DSB repair inhibitors which 
can potently suppress key DSB repair pathways with little toxicity, and in a manner 
unique to previously described agents. Our work also reveals a cutting-edge secondary 
assay platform that can be used for mechanism of action studies for other small molecules 
and genes identified from high-throughput screens in the future. 
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Introduction 
Cancer currently ranks second amongst the leading causes of mortality in the 
United States1. At least 2/3 of all cancer patients receive ionizing radiation (IR) therapy at 
some point during the course of their treatment2. The mechanism by which IR induces 
tumor cell death is by producing double-stranded breaks (DSB) in the DNA. Tumor cells 
often contain mutations in various DNA repair genes, causing them to be overly reliant 
on compensatory pathways in order to repair damaged DNA. DNA-damaging agents are 
amongst the most common form of chemotherapeutics. An estimate of the DrugBank 
database suggests that 68% of all small-molecule chemotherapeutics target DNA3. Of all 
forms of DNA damage, including cross-links, alkylation, single-strand breaks, and DSBs, 
DSBs are the most cytotoxic4. A single unrepaired DSB is may be sufficient to induce 
cell lethality5. Therefore, one common and effective therapeutic approach has been to 
develop small-molecule inhibitors of DNA repair by inhibiting the DSB-repair pathway6. 
These molecules are often given in conjunction with IR to maximize efficacy, a process 
that is known as chemo- or radio-sensitization. 
The DNA damage response pathways (DDR) enable a cell to sense DNA damage, 
initiate repair, and activate signaling pathways that delay or arrest cell cycle progression. 
Initial DNA damage is detected by two proteins: H2AX and 53BP1, which are 
responsible for recruiting other factors involved in the DNA repair cascade. The cell then 
undergoes one of a limited number of pathways of DSB repair. The two main pathways 
are homologous recombination (HR) and non-homologous end joining (NHEJ)7. In HR, 
the cell uses homologous DNA sequences as a template for repair, while in NHEJ, the 
cell reprocesses and relegates the broken DNA strands, a process that is often error-
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prone, leading to insertions and deletions. NHEJ can be further subdivided into canonical 
(cNHEJ) and noncanonical (ncNHEJ) or alternative NHEJ (aNHEJ). The canonical 
pathway has been better characterized, with critical proteins including DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs), the Ku70 and Ku80 heterodimer, X-ray 
cross-complementing-4 (XRCC4) and ligase IV. Meanwhile, proteins that play a critical 
role in the ncNHEJ pathway include ligase III (LigIII), ligase I (LigI), XRCC1 and 
poly(ADP-ribose) polymerase-1 (PARP-1), although several reports have called into the 
question whether LigIII and XRCC1 are actually required for these alternative NHEJ 
pathways8-10, illustrating the need for further study and elucidation of the requisite steps 
in this pathway. While HR primarily occurs during the S-phase of the cell cycle, NHEJ 
occurs during the G1 and G2 phases, making it the more prevalent of the two pathways. 
Examples of key HR proteins include BRCA1, BRCA2, CtIP, and Rad51.  
Although the potential of DDR inhibitors as chemotherapeutic adjuvants has been 
appreciated for at least a decade, most discovery efforts have focused on identifying 
molecules that inhibit specific DDR factors in vitro. For example, PARP-1 inhibitors11, 
one of the first FDA approved drugs to target DNA repair12, and DNA-PKcs inhibitors13 
have been discovered using enzymatic assays, but permeability, toxicity, and solubility 
limitations have in some instances impeded their clinical use14. While some groups have 
reported whole cell assays to identify novel DDR inhibitors, they have focused on 
specific factors, such as ataxia telangiectasia and Rad3-related (ATR)15 or ataxia 
telangiectasia mutated (ATM)16 kinases. To date, only a handful of DNA repair inhibitors 
have been approved for clinical use, underscoring the need to discover new small 
molecule candidates. However, there is continued need to identify small-molecule 
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inhibitors of DDR that could potentially be used in combination with IR or 
chemotherapy. 
Here, we present the development and validation of a novel automated and high-
throughput secondary assay platform for evaluating potential small-molecule inhibitors of 
DNA repair. This includes an adherent cell, imaging cytometry platform to rapidly assay 
GFP- and RFP-based reporter cell lines in 96-well microplates, to assess DNA content 
and S-phase proliferation, as well as to perform miniaturized clonogenic survival assays. 
We then used this platform to characterize hits from previous multiple drug screens, in 
which we identified HSP90 inhibitors and cardiac glycosides as novel DNA repair 
inhibitors. Both groups of compounds potently inhibit both NHEJ and HR with minimal 
toxicity or effects on cell cycle. Furthermore, we were able to show radiosensitization in 
vitro for the HSP90 inhibitors using the clonogenic survival assay. This imaging platform 
provides a cost-effective and high-throughput manner in which compounds can be 
rapidly assessed in vitro for any effects on DNA repair, cell cycle, and radiosensitization, 
enabling investigators to simultaneously report on multiple activities critical to the 
evaluation of a compound as a potential radiosensitizer.  
Materials and Methods. 
Cell lines and reagents. 
U2OS cell line was obtained from American Type Culture Collection (ATCC). U2OS cells 
were cultured in McCoy’s 5A media (Fisher Scientific) supplemented with 10% fetal 
bovine serum (FBS, Life Technologies). All cells were maintained at 37 °C with 5% CO2. 
Mirin was purchased from Sigma-Aldrich, while NU7441 was purchased from Fisher 
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Scientific. The Click-iT® EdU Alexa Fluor® 488 Flow Cytometry Assay Kit was 
purchased from ThermoFisher Scientific. Mibefradil, RU-0093845 (A), RU-0095879 (B), 
RU-0107401 (C), RU-0093823 (D), RU-0093850 (E), RU-0001107 (F) were ordered from 
the Rockefeller University Screening Center as dry powders and stored in DMSO for dose 
response studies. Strophanthidin (1, Sigma-Aldrich), ouabain (2, MP Biomedicals), 
lanatoside C (3, Sigma-Aldrich), ouabagenin (5, Sigma-Aldrich) and digoxigenin (6, 
Sigma-Aldrich) were purchased as dry powders and diluted in DMSO for dose response 
studies. 
Secondary DSB Repair Assays. 
The GFP/RFP-based DSB repair assays were performed using a U2OS cell line with stably 
integrated NHEJ and HR repair reporters (referred to as the EJ-DR assay), combined with 
a ligand-dependent I-SceI (ddSceGR). Ligand-induced DNA cleavage by ddSceGR was 
performed by adding the Shield1 and Triamcinolone Acetonide (TA) ligands at 
concentrations of 0.5–1 M and 100 nM, respectively, to the cell cultures arrayed in 96-
well microplates. Compounds were then added at the indicated concentrations. Ligands 
and compounds were incubated in the cells for 24 h, followed by 1–2 washes with DMEM 
containing 10% FBS without ligands. NHEJ and HR repair activity was assessed by 
quantification of the percentages of DsRed+ and GFP+ cells, using an automated 
fluorescence imager (Cytation3, Biotek Instruments). Standard compensation techniques 
were used when GFP and DsRed were analyzed simultaneously in order to minimize 
spectral overlap. DsRed+, GFP+ and parental cells were used as controls for optimization. 
The data was analyzed using FlowJo (Tree Star, Inc.). Experiments were performed in 
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either triplicate or quadruplicate, and error bars represent standard errors of the mean 
(SEM).  
Immunofluorescence (IF). 
Cells were fixed with 4% paraformaldehyde (PFA, Electron Microscopy Sciences) in the 
presence of 0.02% Triton X100 at room temperature for 20 min, and then incubated in 
permeabilization/blocking solution (10% fetal bovine serum, 0.5% Triton X100 in 
Phosphate Buffered Saline (PBS)) at room temperature for 1 h. Primary antibodies for 
BRCA1 (Santa Cruz sc-6954)] were diluted 1:500 in permeabilization/blocking solution 
and used to stain cells at 4 °C overnight. The secondary antibodies used were Alexa Fluor 
488-conjugated goat anti-mouse IgG and Alexa Fluor 647-conjugated goat anti-rabbit IgG 
(Molecular Probes). Cells were co-stained with the nucleic acid dye Hoechst 33342 
(HOECHST; em = 460 nm) to visualize the nuclei. Immunofluorescence staining was 
performed in 384-well plates using liquid handlers. 
DNA Damage Foci Imaging Analysis 
Cells were imaged using the InCell 2200 Imaging System (GE Corporation). Automated 
image analysis protocol for the quantitative assessment of BRCA1 foci was developed 
using the InCell Analyzer software (GE Corporation). Nuclei were segmented based on the 
nuclear HOECHST staining channel, foci were identified based on the BRCA1 
fluorescence channel, nuclei and foci were then linked, and the number of foci per nucleus 
were counted. Cell-level distributions of foci number per nucleus were generated from at 
least 450–600 cells/well. A threshold of 15 foci per nucleus was set as defining BRCA1 
positive cells. 
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Cell Cycle Profiling. 
Cell cycle phase distributions were assessed by the analysis of DNA content using 
HOECHST staining of cell nuclei. In these experiments, cells were fixed in 70% ethanol 
at the indicated timepoints in 96-well microplates, washed with PBS, and then stained with 
1 µg/ml HOECHST dye. HOECHST fluorescence was quantified using the Cytation3 
automated fluorescence imager. Data analysis was performed using standard FloJo cell 
cycle profiling tools. 
Results 
Development of an automated and high-throughput platform to analyze fluorescent based 
whole cell assays 
We previously developed our fluorescent, cell-based, ligand inducible dual NHEJ 
and HR reporter assay and validated it extensively through pilot screens17. A schematic of 
this assay is shown in Figure 1A. This system comprises both the EJ-RFP assay, which 
measures ncNHEJ, and the DR-GFP assay, which measures HR. Briefly, the EJ-RFP repair 
assay is based on a tetracycline-dependent regulatory system, and it consists of a repair 
substrate and a reporter vector. The I-SceI recognition site 
[TAGGGATAA^CAGGGTAAT] was inserted in-frame between the start codon and the 
open reading frame (ORF) of the tet repressor (TetR) gene in the repair substrate. The 
reporter vector contains a DsRed gene driven by a cytomegalovirus (CMV) promoter with 
an intervening TetR-binding site. Under normal conditions, the TetR protein binds to the 
TetR-binding site and basally represses DsRed expression. Cleavage of the I-SceI site and 
subsequent rejoining of the free DNA ends by error-prone ncNHEJ results in disruption of 
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the TetR ORF. This prevents TetR protein production and enables consequent expression 
of DsRed.  
 
Figure 1. Initial design of a ligand-inducible fluorescent whole-cell reporter assay for 
DSB repair inhibitor screening. (A) A schematic of the EJ-RFP (left) and DR-GFP (right) 
assays to measure ncNHEJ and HR, respectively. Inset on the right, the ddSceGR system 
for ligand-dependent DSB induction. (B) A schematic depicting the timeline associated 
with the use of the EJ-DR assay to evaluate the effect of small molecules on DSB repair 
activity, which consists of six steps: (i) cell seeding, (ii) test compound addition, (iii) DSB 
induction, (iv) ligand and compound wash-out, (v) incubation to permit repair and reporter 
gene expression, and (vi) analysis of RFP- and GFP-positive cells indicating DSB repair 
events.  
 
In the DR-GFP system, the 24-bp recognition site of I-SceI has been integrated into the 
GFP gene such that it disrupts the ORF of the gene. Repair of the cleaved I-SceI site by 
HR gives rise to a functional GFP gene, when the template used for repair is a truncated 
GFP fragment located downstream in the plasmid. RFP- and GFP-positive cells are 
typically measured by flow cytometry to assess ncNHEJ and HR repair activity, 
respectively. Our inducible I-SceI protein contains a modified destabilizing FKBP12 
domain on the N-terminus, and the ligand-binding domain of the glucocorticoid receptor 
(GR) on the C-terminus (referred to as ddSceGR). The addition of the small molecule, 
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Shield1, blocks the destabilizing effect of the N-terminal domain, and the addition of the 
synthetic glucocorticoid receptor ligand, triamcinolone acetonide, induces translocation 
from the cytoplasm to the nucleus. We recently created a U2OS cell line containing single 
copies each of EJ-RFP, DR-GFP, and ddSceGR (referred to as U2OS EJ-DRs cells), and 
we extensively validated its function as a reliable and dynamic reporter of DSB repair, 
using a panel of small interfering RNAs (siRNA) and selected small molecule DSB repair 
inhibitors17. We also characterized the timing and kinetics of this assay with regard to DSB 
cleavage activity and maturation of the RFP and GFP signal, which is depicted in Figure 
1B. 
In our previous studies involving U2OS EJ-DRs cells, we analyzed the percentages 
of RFP- and GFP-positive cells by flow cytometry18. Although this approach is associated 
with high levels of sensitivity and low error rates, it is not well suited for the analysis of 
small numbers of cells grown in 96- and 384-well microplates. To this end, this assay had 
previously been automated using the ImageXpress Velos laser scanning cytometer at the 
Rockefeller University, capable of imaging a single 384-well plate in 5-10 minutes18. 
However, this was a rather expensive method and not feasible for most laboratories that 
lack access to a high throughput drug screening facility. Therefore, we took a more cost-
effective approach that can be undertaken by any laboratory and in which the entire assay 
can be done in-house. We used the Cytation3, a benchtop automated fluorescent imager, 
to capture images under various fluorescent channels on our microplates and analyzed 
those images using CellProfiler v2.1.1, an open-source image analysis software developed 
by the Broad Institute at MIT. This approach was more suitable for analyzing a large 
number of samples, as there was no longer a need to trypsinize individual wells, transfer 
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them to flow cytometry tubes, and analyze each tube manually. Instead this was converted 
to an adherent-cell assay, which enabled rapid assessment and analysis of any cell-based 
fluorescent assay. 
The development of this protocol required the optimization of variables including 
plate type, fixation and staining settings, imaging parameters, and image analysis. The 
process flow for our automated fluorescent assay platform is shown in Figure 2A. First, we 
had to select a 96-well microplate that was well adapted for fluorescent assays. While our 
clear, round-bottom polystyrene plates were adequate for cell growth and subsequent 
transfer to FACS tubes for analysis, they fared poorly for analysis under the Cytation3. 
These plates created a significant amount of autofluorescence which prevented any 
meaningful analysis in the vast majority of wells. Therefore, we switched to a Greiner 
black-walled glass bottom microplate, which is highly adapted to applications in which 
low autofluorescence and high optical clarity are required.  
Next, we experimented with various forms of cellular fixation and staining. We 
reasoned that fixation would provide us with a snapshot or a representation of cellular 
fluorescence at a particular time point. As the Cytation3 takes approximately 1.5 hours to 
image a 96-well microplate on two channels, a live cell analysis would introduce the issue 
of confounding as the last well imaged would have an extra 1.5 hours of metabolic activity 
compared to the first well, precluding any meaningful comparison amongst wells. 
Furthermore, we wanted the flexibility of being able to store the plates in 4oC and imaging 
them at a later time, without any significant alteration in the data. While ethanol is generally 
a robust fixative, in our experience it has been known to denature the GFP protein, making 
it inadequate for use in this case. Therefore, we sought to use paraformaldehyde (PFA), a 
10 
 
known fixative that we successfully used in prior screens18. Our experiments revealed that 
1% PFA, compared to 2% or 4%, was the optimal concentration to use when fixing plates. 
While the Cytation3 would capture all cells that were GFP+ or RFP+, we needed a method 
to normalize to all cells in the well. Therefore, we stained each well with HOECHST 
(H33342) dye, which was detected under the DAPI channel, and whose emission spectrum 
shared little to no overlap with the GFP or RFP spectra.  
Then, we began to optimize the imaging parameters under the Cytation3 and 
analysis under CellProfiler. The two lenses under which we could capture the images were 
a 4X lens and a 10X. We initially optimized under the 10X lens, which afforded stronger 
resolution and potentially increased accuracy. Once the images were captured, we began 
to analyze them on CellProfiler. Briefly, CellProfiler is broken down into input and analysis 
modules. Input modules allow the user to modulate and determine the how data is provided 
to CellProfiler. Analysis modules process and extract information from the image data in 
a manner that is desired by the user. The input and analysis modules put together all form 
a pipeline. For analysis of the EJ-DR assay, the main steps in this pipeline include 
subtraction of background fluorescence, identification and segmentation of individual 
cells, and counting the number of cells under the GFP and DAPI channels. Because the 
RFP is a whole-cell stain in the EJ-RFP assay, while the GFP is a nuclear stain in the DR-
GFP assay, the GFP signal is superior at segmenting. Therefore, to capture total RFP per 
well, we measured total RFP fluorescence and normalized that to total cell count (as 
detected by DAPI+ cells). This data is then automatically exported to an Excel spreadsheet. 
Now that we had established a fixing and staining, imaging, and analysis platform 
for the EJ-DR assay, we sought to compare our results to the gold standard of flow 
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cytometry. We plated duplicate plates containing known proportions of cells with varying 
GFP and RFP positivity. One plate was measured by flow cytometry, and the other plate 
measured by Cytation3 and CellProfiler. The results were plotted against each other and 
were nearly identical, demonstrating a 99% correlation between both techniques. The 
problem with this imaging technique, however, was the incredibly low throughput. For 
example, the time required to image an entire 96-well plate under three fluorescent 
channels in a 10X lens is 13 hours, with the program capturing 70 images per well under 
each channel, with a total of 20,160 pictures taken for a total microplate. We therefore 
decided to optimize imaging under the 4X lens instead, which would instead capture 12 
images per well under each channel, with a total of 3,456 pictures in a 1.5 hour time frame. 
This was much more feasible for any high-throughput drug screening and analysis. We had 
to modify our CellProfiler pipeline since the input images were now considerably smaller 
and use a masking strategy in the pipeline to identify the GFP+ and RFP+ cells. This 
strategy employed the idea that rather than searching through the entire image for the GFP+ 
and RFP+ cells, the program would only search through the DAPI+ cells, thereby ignoring 
the background and reducing the likelihood of the program falsely identifying any 
moderately fluorescent background as a GFP+ or RFP+ cell. We compared the results of 
this platform now under the 4X lens to that of the FACS calibur and found nearly identical 
results. 
Next, we validated our new imaging and analysis platform using known drugs that 
inhibit various components of the DNA repair pathway. We tested mirin (an MRN complex 
and HR inhibitor), NU7441 (a DNA-PK and cNHEJ inhibitor), and mibefradil (a ncNHEJ 
inhibitor) all in multiple doses and compared analysis using flow cytometry to our 
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platform. We found the comparison to be virtually identical (data not shown). Furthermore, 
while analysis of an entire plate would take nearly 4-5 hours under the conventional cell 
suspension and flow cytometry method, with manual input required at every step, our new 
adherent cell platform could analyze an entire plate in 1.5 hours with little to no manual 
input besides the initial fixation and staining. We have also used this platform to rapidly 
and efficiently analyze other fluorescent based whole-cell assays, such as the total NHEJ, 
single-stranded annealing (SSA), and microhomology-mediated end joining (MMEJ).  
 
Figure 2. Schematics depicting process flows for all three secondary assays in our 
high-throughput and automated platform. (A) A schematic of the DNA content and S-
phase proliferation platform used to obtain cell cycle phase data. (B) A schematic of the 
whole-cell fluorescent reporter assay platform in this scenario displaying the EJ-DR assay. 
(C) A schematic of the clonogenic survival assay platform using the EdU Click-iT® assay 
to assess for reproductively active versus senescent cells days after irradiation. 
Development of an automated and high-throughput platform to analyze DNA content and 
S-phase proliferation 
 An important aspect of any small molecule screen for DNA repair inhibitors is that 
any putative hits must be evaluated for potential effects on the cell cycle. For example, it 
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is well known that NHEJ predominates during the G1 phase while HR is more common 
during S-phase. If a compound were discovered, using our fluorescent whole-cell screen, 
that could potentially inhibit the HR pathway, we would want to know that this compound 
truly inhibits HR, and does not in fact arrest the cell in G1, which would also shift the cell 
away from HR and more towards NHEJ repair. Therefore, we adapted our platform so that 
it can measure DNA content as well as S-phase proliferation (Figure 2B).  
 The conventional standard in which DNA content is measured is using 70% ethanol 
fixative, propidium iodide (PI) dye, and ribonuclease I. Briefly, cells are harvested from 
tissue culture and placed into polypropylene flow cytometry tubes. They are centrifuged, 
pelleted, and fixed with the addition of 70% ethanol for two hours. They are then re-
suspended and stained with PI, and then analyzed on flow cytometry. A normal log-phase 
distribution of cells contains 60% in the G1 phase, 20% in the S-phase, and 20% in the G2 
phase. As with the fluorescent whole-cell assays, this technique is accurate and reliable for 
individual samples, but is cumbersome and low-throughput for screening purposes. 
Therefore, we adapted the conventional protocol to a 96-well microplate format. We plated 
U2OS cells overnight in 96-well CoStar black-walled, flat, clear bottom microplates. The 
next day, we fixed the cells with 70% ethanol within the microplate for two hours and 
washed out the ethanol with PBS. Then we added 1 ug/mL H33342 dye per well and 
incubated in the dark for 15 minutes. We imaged the plate with the Cytation3 under the 
DAPI channel using the 4X lens, with a total imaging time of 30 minutes. The images were 
then analyzed under a new CellProfiler pipeline. The pipeline strategy was as follows: 
background subtraction, cell identification and segmentation, integrated intensity 
measurement of each cell, and data export to an Excel document. The integrated intensity 
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data from each well was exported to a separate spreadsheet, thereby creating 96 
spreadsheets – one for each well. From there, the spreadsheets, which were in .csv format, 
were converted into FCS files using FlowJo, a standard flow cytometry analysis software. 
Using FlowJo, we were able to create 96-well plate maps, which represent a collection of 
DNA content histograms for each well in the same distribution and organization as the 96-
well microplate. An example is given in Figure 3A. With these plate maps, we could now 
rapidly assess trends in DNA content across an entire plate in a visually accessible manner.  
 We further added another component to the cell cycle platform, which was the rapid 
quantification of the proportion of cells in G1, S, and G2 phases across a large number of 
samples. Current software like FlowJo, Modfit LT, or FCS Express require fitting 
individual plots to a curve in order to obtain quantitative information on phase distribution. 
While applicable for a few samples, this cannot be applied to a large number of samples in 
a reasonable timeframe. Therefore, with the help of Gregory Breuer, MD, PhD student in 
the Bindra Lab, we created an automated peak recognition software. This program allows 
the user to input any number of FCS or CSV files to be analyzed. The user manually 
determines the lower and upper boundaries for a reference file, and the program then 
searches for the two largest peaks within the boundaries chosen by the user. For each peak, 
it determines the area under the curve using a Gaussian distribution. The first peak is always 
G1, the second peak G2, and S-phase is calculated as 1 – G1 – G2. This program can 
analyze 96 FCS files within 13 minutes, a marked improvement over conventional phase 
quantification. This program can also analyze FCS files obtained from flow cytometry, 
making it incredibly versatile over a variety of applications. This program provides the 
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investigator with a quantitative counterpart to the visual plate maps, and enables evaluation 
of subtle changes and shifts in cell cycle distribution. 
 We then sought to validate our DNA content platform using drugs known to arrest 
cells in particular phases of the cell cycle. These include etoposide (G2 arrestor), 
hydroxyurea (G1 arrestor), aphidicolin (G1 arrestor), taxol (G2 arrestor), nocodazole (G2 
arrestor), and CPT11 (G2 arrestor). We plated U2OS cells overnight and added these six 
drugs in varying concentrations for 24 hours before ethanol fixation and then H33342 
staining. Indeed, our DNA content plots (Figure 3B) correlated with the expected plots 
from conventional PI staining and flow cytometry.   
 Next, we wanted to test the robustness of this platform across multiple cell lines, 
DNA staining dyes, and microplates. We successfully carried out the same protocol using 
T98G glioma cells and KNS42 astrocytes. Then, we successfully showed that different 
DNA staining dyes, such as Vybrant Orange, Vybrant Green, and Vybrant Ruby, can be 
used with our platform in U2OS, T98G, and KNS42 cells. Finally, we showed that this 
protocol could be adapted for 384-well microplates.  
 While DNA content analysis provides us with a rough snapshot of any cell cycle 
effects of our drugs at a particular time point, we sometimes covet a more dynamic analysis 
of real-time cell proliferation over a designated period of time. This has traditionally been 
assessed via the bromodeoxyuridine (BrdU) proliferation assay. BrdU-labeled DNA is 
quantitated using anti-BrdU antibodies following DNA denaturation by harsh processes 
including acid wash, heat, or enzyme treatment, to expose the BrdU binding sites. This 
process is difficult, time-consuming, low-throughput, and can sometimes affect sample 
integrity by harsh treatment of the DNA. Instead, we sought to use the Click-iT® EdU 
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assay (Thermofisher Scientific). 5-ethynyl-2’-deoxyuridine (EdU) is a thymidine analog 
containing an alkyne and incorporated into DNA during synthesis.  The reaction also 
contains a dye-labeled azide. In a copper-catalyzed reaction, the alkyne reacts with the 
azide and forms a stable covalent bond. This technology is an improvement over 
conventional BrdU since the dye-azide is small enough to access the EdU without any need 
for harsh chemical treatment.  
We adapted this technology for the purposes of analyzing DNA content and S-
phase cell proliferation simultaneously. The protocol we used is as follows: log-phase cells 
in culture are initially incubated with the EdU kit for a period of time (pulsed) and then 
washed with PBS. Cells are then fixed in 70% ethanol, which also permeabilizes the cells 
enough to allow the Alexa 488 dye-azide to covalently bind the EdU moiety. Click-iT® 
EdU detection then occurs with the addition of copper and ascorbic acid. Finally, cells are 
stained with H33342 dye and incubated in the dark for 15 minutes. The Cytation3 imaging 
procedure was altered to incorporate both GFP and DAPI channels, for the EdU and 
H33342 detection, respectively. The DNA content CellProfiler pipeline was altered to take 
into account EdU integrated intensity. Analysis on FlowJo was virtually the same, except 
now the plots were semi-log, and incorporated DNA content on the X-axis and the 
logarithm of EdU fluorescence on the Y-axis. We tested this platform using the same six 
cell cycle arresting drugs that were used to validate the DNA content platform. As can be 
seen in Figure 3C, these plots with S-phase proliferation provide us with added               
information regarding not only the proportion of cells in each cell cycle phase, but also the 
distribution of cells within each phase (early, middle, or late). This further enhances our 
understanding mechanistically of the effect of individual compounds on the cell cycle. In 
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sum, this platform provides us with an invaluable tool to select out any compounds that 
significantly affect cell cycle, while enabling us to screen for true small molecule inhibitors 
of DNA repair.  
 
Figure 3. DNA content and S-phase proliferation platform used to analyze cell cycle 
phase distributions within a population. (A) A typical 96-well plate map created on 
FlowJo (Tree Star, Inc) which is a visual representation of the corresponding 96-well 
plate. These maps are commonly used to evaluate the effect of dose response studies on 
cell cycle phase. Validation of the DNA content (B) and S-phase proliferation (C) 
components of our platform using six known cell cycle arrestors. Cells were treated with 
1.78 μM of each drug for 24 hours. 
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Development of an automated and high-throughput platform to assess for clonogenicity 
and radiosensitivity 
The gold standard for the evaluation of an agent as a radiosensitizer in vitro is the 
clonogenic survival assay (CSA). This is a cell survival assay that assesses the ability of a 
cell to reproduce indefinitely19. The reproductive survival of a cell is defined by its ability 
to grow into a colony of at least 50 cells. Upon treatment with ionizing radiation, or other 
cytotoxic agents, a fraction of the original cells maintain this reproductive potential, while 
the other cells halt replication and enter senescence, or die. While CSAs are highly reliable 
and accurate, they are best utilized when evaluating a small number of treatment 
conditions. The process involves plating cells at various dilutions in 6-well dishes for each 
treatment condition, waiting 1-3 weeks for colonies to form, fixing with glutaraldehyde 
and staining with crystal violet, and counting individual colonies and number of cells per 
colony using a stereomicroscope. For the evaluation of many drugs at multiple doses as 
radiosensitizers, this assay is resource intensive, cumbersome, and time-consuming.  
Prior groups have certainly attempted to automate and miniaturize the CSA into 96-
well microplate format. Katz and colleagues20 published on a 96-well colony formation 
assay in which nuclei are stained with H33342 and cytoplasm with CellTracker Orange. 
The authors used the InCell1000 automated imager with proprietary software to image and 
segment individual colonies, which they defined as anything between 6 and 350 cells. They 
were then able to show reproducibility and equivalent comparison to the traditional 6-well 
CSA. Lin and colleagues21 recently published on their own 96-well CSA in which colonies 
are stained with crystal violet and imaging and analysis occurs with the InCell6000. The 
high content CSA was once again validated by comparing its performance against the 6-
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well CSA. The main issue with these methods is twofold: first, there is no consistent way 
to assess whether colonies are reproductive or abortive. While the 50 cell per colony rule 
may work for larger 6-well dishes, applying this rule to a miniaturized 96-well plate may 
result in selecting out many colonies that are truly replicative. Furthermore, while the 50 
cell rule was created by Puck and Marcus22, the original developers of the CSA, to serve 
as a proxy for a colony with indefinite replicative potential, perhaps we can assess 
clonogenicity through another means. Secondly, both techniques used the InCell imager, a 
rather expensive machine that would typically only be found in drug screening facilities 
and not generally used by individual laboratories.  
To address these issues, we created our own version of the automated and 
miniaturized CSA. The process flow for this assay is shown in Figure 2C. To assess 
clonogenicity, we used the compound EdU, the same molecule that was used in our S-
phase cell cycle proliferation platform. We reasoned that upon treatment with ionizing 
radiation, a small fraction of cells replicate indefinitely, and the others become abortive 
after one or two cell cycles. If a cell were truly replicating, we would expect it to take up 
EdU sometime during a 24 hour period. We also wanted to adapt our Cytation3 and 
CellProfiler platform to this CSA. To this end, we began by plating Chinese Hamster Ovary 
(CHO) cells, which are known to produce excellent and tightly knit colonies, into 96-well 
plates at various densities. We noticed that on average, colonies would form after 6 days 
with the CHO cells. After 6 days, we fixed the cells in 70% ethanol, stained them with 
H33342 dye, and imaged them on the Cytation3. We then created a pipeline on CellProfiler 
to both count the colonies and the number of cells within each colony. This protocol was 
repeated and optimized for the KNS42 cell line, which we preferred due to its derivation 
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from human tissue. Next, we incorporated the EdU Click-iT® assay into our CSA.  We 
made four replicate plates of KNS42 cells at various dilutions in a 96-well plate. Each plate 
was grown overnight and then received different doses of irradiation using our Cesium 
irradiator (0, 2, 5, or 10 Gy). The plates were then grown for eight days to allow colony 
formation; by this time most abortive cells will have entered senescence or died by 
apoptosis or mitotic catastrophe. The EdU Click-iT® kit was then added to all four plates 
for a period of 24 hours, the estimated length of time to complete one cell cycle. Any truly 
replicating cell will have undergone S-phase at least once during this period and so will 
have taken up EdU. Therefore, the colonies in which the vast majority of cells are EdU+ 
are truly clonogenic, while those in which the cells are primarily EdU- are abortive. The 
EdU is then washed out and the plates fixed in 70% ethanol and stained with H33342 dye. 
Analysis takes place on our Cytation3 and CellProfiler platform. An example of this EdU 
filter can be seen in Figure 4A. As can be seen in the DAPI+ image, the CellProfiler 
program detects all clusters of cells as colonies. However, some of those cell clusters are 
not truly clonogenic, and can therefore be eliminated when the same image is taken on the 
EdU+ filter. 
Next, we tested our new EdU based CSA platform with the known radiosensitizer 
NU7441. As described previously, NU7441 is a DNA-PK inhibitor that functions as a true 
radiosensitizer – it exerts little to no cell toxicity in the absence of ionizing radiation (IR), 
but strongly enhances tumor cell kill in the presence of IR. We tested the effect of CHO 
cells in the presence of DMSO alone, 0.25 μM, or 2.5 μM NU7441 at doses of 0, 2, 5, or 
10 Gy. Our data showed steeper cell survival curves with the increasing doses of NU7441 
(Figure 4B), consistent with what has been reported in the literature. We have yet to 
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validate this platform for other known radiosensitizers and compare these results to the 
traditional CSA.  
 
Figure 4. Miniaturized clonogenic survival assay platform using Click-iT® chemistry. 
(A) Images taken of KNS colonies from a single well within a 96-well plate 10 days after 
plating. These cells were pulsed with EdU-Alexa 488 for 24 hours, fixed in 70% ethanol, 
and stained with H33342 dye. The same image was taken under the DAPI (left) and GFP 
(right) channels and depicts how the Edu is used to filter out abortive colonies that take up 
only H33342 dye. (B) Validation of the CSA platform using NU7441, the DNA-PK 
inhibitor, as a radiosensitizer. CHO cells were plated at various densities with 0, 0.25 μM, 
or 2.5 μM of NU7441 and irradiated at 0, 2, 5, or 10 Gy. Edu pulsation occurred on Day 4. 
The survival curves show greater cell kill with increasing doses of radiosensitizer.  
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Characterization of novel HSP90 inhibitors using our high-throughput and automated 
secondary assay screening platform 
 Our group previously performed a high-throughput drug screen using a 20,000 
compound diverse small molecule library, a subset of a larger 150,000 compound library 
from the Rockefeller University18. All compounds were tested in singlicate at 10 μM in the 
EJ-DR assay, with a hit defined as any compound that significantly inhibited cellular GFP 
or RFP fluorescence beyond a predetermined threshold. Any compounds that caused 
significant cell toxicity were eliminated. Approximately 750 hits were obtained from this 
screen, and further testing and validation led to the identification of 16 final hits. All 16 
hits were counter-screened to ensure that the compounds themselves were not inhibiting 
fluorescence, but rather inhibiting DNA repair. One compound, RU-0093845 (A), was 
found to significantly inhibit ncNHEJ and HR, with minimal effects on cell viability even 
at the highest dose tested (50 μM), as shown in Figure 5A.  
To further learn about the structural properties that confer potency on this 
compound, we performed an in silico search of the entire 150,000 compound library for 
compounds structurally similar to our index hit. We identified five compounds (B, C, D, 
E, F) with a high level of similarity and tested them in the EJ-DR assay at various doses 
using our platform. We found that compounds B and C showed marked activity in the assay 
and inhibited both HR and ncNHEJ to levels comparable to compound A. Meanwhile, 
compounds D, E, and F showed almost no activity in the assay. Upon further examination, 
we noticed that the index compound A displayed remarkable structural resemblance to 
radicicol, one of the earliest HSP90 inhibitors developed and tested in clinical trials. We 
then reasoned that perhaps the compounds displaying activity in the EJ-DR assay 
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mechanistically inhibited HSP90. To test this hypothesis, we collaborated with Dr. 
Gabriela Chiosis at Memorial Sloan Kettering Cancer Center, in which we sent compounds 
B, C, D, and E to run in the in vitro HSP90 binding assay developed by her group23. This 
is a competitive binding assay that assesses for the ability of increasing doses of a test 
compound to displace the HSP90 inhibitor geldanamycin from the HSP90 N-terminus. All 
test compounds were compared to the control HSP90 inhibitor, PU-H71. The results from 
this experiment revealed that compounds B and C, which displayed activity in the EJ-DR 
assay demonstrated remarkable binding to HSP90, while compounds D and E which 
exhibited minimal activity in the EJ-DR assay, showed no in vitro binding to HSP90 
(Figure 5B).  
Having established that the three hits likely exerted their potency as HSP90 
inhibitors, we sought to compare their phenotype with that of known HSP90 inhibitors 
through a series of secondary assays. First, we compared compounds A, B, and C to PU-
H71 in the EJ-DR assay. We found that all compounds markedly repressed HR and 
ncNHEJ. However, the three hits were virtually non-toxic at all doses, while PU-H71 was 
toxic at all doses tested. Representative data comparing compound B to PU-H71 in shown 
in Figure 5C. Toxicity was measured by total cell count in the EJ-DR assay, both 24 and 
96 hours after drugs are added. This suggests that our compounds could be likely combined 
with IR without suffering from the combined toxicity that plagued many of the earliest 
HSP90 inhibitors tested in clinical trials24. We then validated compounds B and C through 
the DNA content component of our high-throughput platform. Multiple doses between 0.78 
μM to 50 μM were tested for both compounds. The data revealed no effect on DNA content 
distribution for both compounds at nearly all doses tested with the exception of 50 μM for 
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compound B, which showed marked G2 arrest (Figure 5E). This suggests that at least two 
of the hits truly inhibit DNA repair and have no effect on the cell cycle.  
 
Figure 5. Analysis of the effects of novel HSP90 inhibitors on DSB repair activity. (A) 
The original index hit A discovered in our 20,000 compound Rockefeller University 
Library screen. The graph of repair activity (middle) depicts dual suppression of both HR 
and NHEJ, while the toxicity graph (right) shows no effect on cell number at all doses 
tested. (B) The results of the HSP90 in vitro competitive binding assay. Compounds B and 
C displayed potent binding to HSP90, while D and E showed no binding to HSP90. (C) 
Repair activity data comparing compound B to PU-H71, an HSP90 inhibitor. Compound 
B displayed no toxicity at any dose, while PU-H71 exhibited toxicity at all doses tested. 
(D) BRCA1 DNA Damage foci assay comparing compound B to radicicol and PU-H71. 
Compound B did not inhibit foci at any dose tested while PU-H71 and radicicol suppressed 
foci at high doses. (E) Representative cell cycle phase histograms for compounds B and C 
at selected concentrations.  
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We then sought to compare our hits to HSP90 inhibitors in DNA damage foci 
assays. Briefly, the DNA damage foci assay measures the response of DNA damage 
proteins to DSBs. Upon induction of IR, or any genotoxic agent, proteins involved in the 
DDR accumulate at the sites of DSB and form foci, which can be detected via fluorescent 
antibodies to targeted proteins. For example, a compound that inhibits a certain protein in 
a DSB repair pathway may result in fewer foci for proteins involved downstream of that 
pathway. In collaboration with Yulia Surovtseva at the Yale Center for Molecular 
Discovery, we compared compound B to PU-H71 and radicicol in BRCA1 foci assays. The 
range of doses tested for each compound were the following: Radicicol: 0 – 10 μM, PU-
H71: 0 - .1 μM, and compound B: 0 – 10 μM. Our data showed that while both radicicol 
and PU-H71 inhibited BRCA1 foci at the highest doses, compound B showed no BRCA1 
inhibition at any dose (Figure 5D), suggesting a potentially different mechanism of action 
compared to known HSP90 inhibitors.  
Finally, we examined the ability of the index hit, compound A, to radiosensitize in 
vitro. To this end, we carried out a traditional CSA in which we tested IR with or without 
the compound at 10 μM at doses of 0 and 2 Gy.  Our results showed no difference in cell 
survival at 0 Gy, but a 30% cell survival with IR and compound A at 2 Gy, compared to 
47% cell survival at 2 Gy with IR alone (data not shown).  This result suggests that our hit 
putatively functions as a true radiosensitizer, presenting with a strong phenotype in the 
presence of IR, but minimal toxicity as a singular agent.  
Characterization of cardiac glycosides as novel DNA repair inhibitors using our high-
throughput and automated secondary assay platform 
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We recently performed another high-throughput screen, implementing an 
automated foci-detection platform that we developed in collaboration with the YCMD. 
This screen incorporated three different compound libraries, including the NIH Clinical 
Collection (BioFocus DPI), the FDA Approved Drug Library (ENZO Life Sciences), and 
a Yale Center for Molecular Discovery Yale Procured Drugs custom collection, which 
totaled 2,366 compounds. The primary aspect of this screen selected for compounds that 
inhibited or delayed foci resolution for γH2AX and 53BP1, key DDR components that 
recruit many other mediator and effector proteins and chromatin-modifying complexes to 
DSBs. γH2AX amplifies the DNA damage signal and localizes several NHEJ and HR 
proteins, including 53BP1, onto the damaged DNA.25 53BP1 recognizes a unique DSB-
specific histone code and acts in conjunction with factors downstream of ATM to promote 
NHEJ and suppress HR repair in certain contexts.26 γH2AX and 53BP1 form cytologically-
detectable foci that can be visualized by immunofluorescence microscopy.27,28 This screen 
identified strophanthidin (1), ouabain (2), lanatoside C (3), and digoxin (4, Figure 6A), 
which uniquely elevated H2AX foci with concomitant suppression of 53BP1 foci levels. 
These hits were of great interest, because they suggested a functional suppression of 
proximal DNA damage signaling (53BP1 foci suppression) and disruption of DSB 
rejoining (delayed H2AX foci resolution). Moreover, the structural similarity of the 
aglycon residues of 1–4 suggests specific recognition with a DDR target. 
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Figure 6. Analysis of the effects of cardiac glycosides on DSB repair activity. (A) 
Chemical structures of the cardiac glycosides 1–4. (B) Effects of 1–3 on HR and mutagenic 
NHEJ repair at a range of drug doses; the fraction of cells in G1-phase, along with total 
cell counts, are shown for each dose. (C) Representative cell cycle phase histograms for 
the corresponding active compound concentrations from the DSB repair assays presented 
in (B) are shown for each compound. 
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We then sought to focus on these four compounds and run them through our 
automated and high-throughput screening platform described previously in this 
manuscript. The effects of 1–3 at concentrations of 0.300–5 μM on DSB repair were 
evaluated in these assays. As shown in Figure 6B, 1–3 suppressed both NHEJ and HR 
repair independent of cell toxicity, and no significant alterations in cell cycle distributions 
were observed (Figure 6C). Ouabain (2) displayed the most potent phenotype, with an 
approximately 60% reduction in both NHEJ and HR repair activity at a concentration of 
38 nM. Substantial DSB repair inhibitory activity was observed even at <20 nM for 2. DSB 
repair inhibition correlated with cell toxicity for this drug, but there were no changes in the 
G1-phase fraction under these same conditions. Thus, toxicity appeared cell cycle-
independent, and could not explain the phenotype of this drug on DSB repair. 
Diphenylcyclopropenone was also included in these studies, which validated as a hit 
initially, but it was excluded because it was found to induce DNA damage in absence of 
IR (data not shown). As expected, this hit did not demonstrate any activity in these assays, 
which detect DSB repair specifically at two site-specific, induced DSBs. These data 
highlight the specificity of this assay for DSB repair activity.  
We also evaluated the activity of the isolated aglycones of 2 and 3 [ouabagenin (5) 
and digoxigenin (6), respectively, Figure 7A] in this repair assay to ascertain the influence 
of the carbohydrate residues of 2 and 3 and obtain preliminary structure–function data on 
the aglycon substructures. Both 5 and 6 displayed comparable, albeit less robust, NHEJ 
and HR inhibitory activity (Figure 7B). Negligible effects on cell toxicity were noted at the 
doses observed (data not shown). Cell cycle analysis did not provide any evidence of cell 
cycle arrest (Figure 7C).  
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Figure 7. Analysis of the effects of aglycon substructures on DSB repair activity (A) 
Structures of the isolated aglycones of 2 and 3 [ouabagenin (5) and digoxigenin (6), 
respectively]. (B) Effects of ouabagenin (5) and digoxigenin (6) on DSB repair activity in 
the GFP/RFP-based reporter assays (assay schematic shown in Figure 5A). (C) 
Representative cell cycle phase histograms for each drug at selected concentrations from 
the assays presented in (B). 
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Discussion 
 Chemotherapeutics and targeted agents that inhibit DNA repair are currently being 
explored as therapeutic strategies29.  A number of drugs that target various elements of the 
DNA damage response are currently being tested in preclinical and clinical trials, including 
inhibitors of ATM/ATR, CHK1, DNA-PK, LIG4, PARP, RAD51, RPA, and WEE1. 
However, nearly all of these compounds were discovered using target-based 
approaches.15,30,31 A whole-cell unbiased approach promises to provide inhibitors of known 
and unknown protein targets including those that are not readily obtained in purified form.  
 This paper presents a cost-effective platform with which investigators can scale up 
any fluorescent cell based assay into a more automated and high-throughput manner that 
can be used for high-content drug screening. We demonstrated that these assays can be 
performed in 96- or 384-well microplate format, and therefore amenable to large compound 
libraries. This platform comprises three components: fluorescent assay readout, DNA 
content analysis, and clonogenic survival. The common thread between all components is 
the combination of the Cytation3 automated fluorescent imager and CellProfiler image 
analysis software, whose versatility can be employed for a variety of applications. We were 
able to successfully perform a number of fluorescent cell assays including the EJ-DR, total 
NEHJ, SSA, and MMEJ. We were also able to obtain data on drug toxicity at multiple 
timepoints, as measured by total cell count via H33342 staining. The analysis of DNA 
content and S-phase proliferation in a high-content format is a unique feature of our 
platform. While previous groups have published on measuring cell cycle staging in 
microplate format, their approach is rather limited. For example, Misteli and colleagues32 
recently published on a protocol to analyze DNA content in microplate format. Their 
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approach focuses on a single cell line and method of DNA content staining. We present a 
more comprehensive approach that we validated using multiple cell lines and a variety of 
DNA staining dyes. Furthermore, we incorporated EdU S-phase proliferation, which to our 
knowledge has never been miniaturized into microplate format. We also developed a user-
friendly automated peak recognition system to quantify the analysis of this platform. 
Lastly, the clonogenic survival component of this assay is currently in development but has 
had remarkable success thus far. While other groups have automated the CSA into 96-well 
format, they used expensive imaging equipment typically found in drug screening centers, 
along with arbitrary means for defining a colony. Our assay uses the benchtop Cytation3 
imager that can be purchased by any laboratory. We also take a more unbiased approach 
to colony definition, using Edu uptake after ionizing radiation to define the clonogenicity 
of a cell. We have generated strong initial data using this assay with NU7441, and will next 
validate it by comparing these results against the traditional CSA.  
 Our platform was first used to identify mechanistic information about a group of 
six drugs discovered through an in silico search of a 150,000 diverse small molecule 
library. All drugs were tested in the EJ-DR assay and three were found to potently inhibit 
both HR and ncNHEJ. We identified those same three as HSP90 inhibitors through an in 
vitro binding assay. Two were tested in our DNA content component and found to have 
virtually no effect on cell cycle, furthering their case as true DNA repair inhibitors. One 
was tested through a BRCA1 DNA damage foci assay and found to have no effect on 
BRCA1 foci at high doses, in contrast to other known HSP90 inhibitors. That same 
compound was tested through a traditional CSA and found to have radiosensitivity at 2 Gy.  
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 The concept of HSP90 inhibitors as modulators of DNA repair has been suggested 
for some time, but reports on mechanism of action have been inconsistent at best. One 
study by Dote and colleagues33 showed that exposure of pancreatic tumor cells to the 
HSP90 inhibitor 17DMAG inhibited DSB repair as assessed by γH2AX foci and neutral 
comet assay. Furthermore, this compound inhibited phosphorylation of DNA-PK protein 
with no effects on the KU70/80 heterodimer, which occurs more proximally in the NHEJ 
pathway. The authors also found that 17DMAG inhibited formation of the MRN complex, 
an early sensor of DNA damage in the HR pathway. A recent study by Stecklein and 
colleagues34 reported that the HSP90 inhibitor, 17-AAG, induces BRCA1 ubiquitination 
and proteasomal degradation. This abolishes BRCA1-dependent repair and results in tumor 
death by mitotic catastrophe. Other studies have also mentioned the effect of HSP90 
inhibition on various components of the HR pathway, including at BRCA235, RAD5136, 
FANCA37, CHK138, and the MRN39 complex. Another report by Fang and colleagues40 
suggests that HSP90 mediates the interaction between DNA polymerase β and XRCC1, 
two components of NHEJ repair pathway. Our data suggests that our novel HSP90 inhibitor 
may target both major DNA repair pathways.  
 In addition to DNA repair, it has been known for at least a decade that HSP90 
inhibitors can radiosensitize tumor cell lines in preclinical models. Russell and colleagues41 
showed that 17-AAG may act as a true radiosensitizer in two glioma and two prostate 
cancer cell lines with minimal toxicity from the agent alone. This same compound was also 
shown to increase the radiosensitivity of a cervical cancer cell line42 and lung squamous 
carcinoma line43. The mechanism of radiosensitization of HSP90 inhibition has also been 
studied in experimental models. While DNA repair is certainly an established determinant 
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of radiosensitivity,44 many reports point to the ErbB family of proteins that become 
downregulated in response to the HSP90 inhibitor 17DMAG44. These studies have found 
that in cell lines not expressing ErbB3, HSP90 inhibition alone was sufficient to reduce 
ErbB1 signaling and induce radiosensitization. However, in cell lines expressing ErbB3, 
HSP90 inhibition could not abrogate ErbB1 signaling and therefore did not result in 
radiosensitization. Only through siRNA knockdown of ErbB3 could HSP90 inhibition 
radiosensitize these cell lines. Because most clinical trials have focused on HSP90 
inhibitors as monotherapies, there has been little attention devoted to clinical trials 
exploring HSP90 inhibitors as radiosensitizers. A Phase I trial in which patients were given 
radiotherapy, the chemotherapeutic cisplatin, and the HSP90 inhibitor AT13387 was 
recently suspended in December 2015 due to unacceptable toxicity, an issue that has 
plagued radiosensitizer research in general, and HSP90 inhibitors in particular.  
 HSP90 inhibitors have also had a rather tumultuous course as monotherapy 
anticancer agents. When HSP90 was first broached as a potential target for cancer therapy 
in the 1990s, it was viewed with much skepticism, as HSP90 is a relatively broad target 
that plays an important role in both normal and oncogenic processes24. The earliest studies 
with HSP90 inhibitors were carried out with radicicol and geldanamycin, which showed 
that these compounds bound to the HSP90 N-terminus and prevented its association with 
its client protein, SRC, thereby resulting in destabilization of the complex. While these 
drugs themselves were too toxic for human testing, they gave rise to a new generation of 
HSP90 inhibitors (17-AAG, KOS-953, tanespimycin) that soon underwent clinical trials. 
One study showed that 17-AAG has a 100-fold higher binding affinity for HSP90 from 
tumors cells compared to normal cells in vitro, thereby describing the therapeutic window 
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of these drugs45. However, many limitations were soon discovered with these compounds, 
including liver toxicity or P-glycoprotein mediated efflux (seen in tanespimycin). 
Investigators then began to use the X-ray crystal structure of HSP90 to guide rational drug 
design. This led to the purine scaffold series, including compounds such as PU-H71, 
currently in Phase I clinical trials, and STA-9090, another second generation HSP90 
inhibitor developed by Synta pharmaceuticals as a promising agent. Multiple reports have 
demonstrated the ability of STA-9090 to radiosensitize in vitro in colorectal cancer cells46 
as well as human lung adenocarcinoma cells47.  
 However, it is well known that HSP90 client proteins include tumor-driver proteins, 
and it is suggested that tumors addicted to these oncogenes may be most susceptible to 
HSP90 inhibition. One prime example is the tyrosine kinase receptor HER2, which was 
reported nearly two decades ago to be an HSP90 client, susceptible to chaperone 
inhibition48. Preclinical data has shown HSP90 inhibitors to be effective in HER2+ breast 
cancer xenograft studies. This strategy has also been shown to be effective in patients with 
HER2+ breast cancer for whom trastuzumab alone did not halt tumor progression. Another 
example is the tyrosine kinase inhibitor ALK, whose mutation can be found in a subset of 
patients with non-small cell lung cancer (NSCLC). Phase II studies of patients with 
NSCLC treated with the HSP90 inhibitor IPI-504 showed positive response rates in those 
harboring ALK mutations49. Collectively, these studies suggest that HSP90 client proteins 
are involved in numerous pathways, including DNA repair, cell growth, nutrient stress, and 
hypoxia, and we must properly direct our therapies to oncogenes that happen to be HSP90 
clients.  
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 Our platform was then used to identify mechanistic information about a novel group 
of DNA repair inhibitors, cardiac glycosides. Our screen isolated four glycosides with 
strong phenotypes, of which digoxin is currently FDA approved and used to treat patients 
with heart failure. Negligible effects were demonstrated on cell cycle or cell toxicity at all 
time points tested. The structural homology of the aglycon residues of 1–4 suggests 
recognition of a specific target. In accord with this, the aglycones ouabagenin (5) and 
digoxigenin (6) displayed comparable DDR inhibitory activity, although their potency was 
lower than that of 1–4. It is plausible that the carbohydrates of 1–4 may increase cellular 
uptake, or modulate metabolism or target recognition.50-52   
 Cardiac glycosides (CG) are inhibitors of Na+/K+-ATPase53 and many are in 
clinical use for the treatment of heart failure and atrial arrhythmia. However, the idea 
behind using them as anticancer agents has been around since the 1980s54. Stenkvist and 
colleagues reported that breast cancer cells obtained from patients on digitalis therapy 
contained more benign features compared to cells obtained from control patients55-57. 
Furthermore, recurrence rates for patients on digitalis were 9.6 times lower compared to 
patients not taking digitalis. These studies led to a host of in vitro experiments 
characterizing the anticancer properties of CG in various cell lines, including breast, 
prostate, lung, leukemia, neuroblastoma, renal, myeloma, and pancreatic54. The mechanism 
behind the anticancer properties of CG is still being worked out. It is known that tumor 
cells react differently to cardiac CG compared to normal cells, suggesting this may be due 
to differential expression and activity of the Na+/K+ ATPase. One theory suggests that these 
compounds activate the SRC-epidermal growth factor receptor (EGFR)-mitogen-activated 
protein kinase (MAPK) pathway, which results in growth arrest. Another study reports 
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their involvement as DNA topoisomerase II inhibitors58. Yet another intriguing hypothesis 
from Lopez-Lazaro59 posits that CG inhibit aerobic glycolysis, leading to decreased ATP 
synthesis, decreased clearance of reactive oxygen species, and cell death. It is well known 
that cancer cells prefer glycolysis to oxidative phosphorylation, a phenomenon known as 
the Warburg Effect. By inhibiting the Na+/K+ pump, CG concomitantly inhibit glycolysis60 
and therefore lead to tumor cell death. Few clinical trials examining CG as anticancer 
agents have been initiated, despite their expedited pathway to approval due to their well-
known and studied pharmacological properties. A Phase I study of Anvirzel was approved 
for patients with advanced solid tumors. This drug displayed no toxicity, but also exhibited 
no significant antitumor effect and so was not pursued any further. 
 While little is known about the exact mechanism and anticancer properties of 
cardiac glycosides, even less is known about their role in DNA repair and 
radiosensitization. A recent report by Jun and colleagues61 suggests ouabain inhibits the 
Fanconi anemia/BRCA pathway. Another study by Hiyoshi and colleagues62 suggests that 
ouabain, in a low dose that marginally inhibits the Na+/K+ pump, stimulates the DDR 
pathway and activates γH2AX. One study reports that human lung adenocarcinoma cells 
were radiosensitized with low concentrations of ouabain63. Another study showed that 
ouabain enhances the effect of radiation in a number of human cancer cell lines64. 
Therefore, there is a pressing need to study the DNA repair properties of CG and to further 
understand contexts in which they can enhance the therapeutic index in radiation therapy. 
Drug repurposing has recently gained traction as a means to quickly progress compounds 
that have cleared key developmental milestones toward new clinical applications, as 
exemplified by the recent approval of thalidomide (a drug once used to treat morning 
37 
 
sickness but later identified as a teratogen)65 for the treatment of lymphomas,66 and the use 
of FDA-approved ion channel blocking agents as anti-cancer agents.67-71 Moreover, our 
data suggest a basis for the poorly-understood53 anticancer activity of many cardiac 
glycosides, and argue that this DDR activity should be considered when evaluating their 
clinical applications toward other diseases. 
 Although there are many advantages to a DNA repair inhibitor screen using an 
unbiased, whole-cell approach, there are some limitations. While most drug discovery 
studies begin with identifying a drug’s target or mechanism of action, we take the reverse 
approach. When starting with a phenotype and narrowing the focus to a mechanism of 
action, there is always the possibility that the target is not specific to DNA repair. Although 
we do attempt to eliminate the major confounder of cell cycle effects, there may be others 
that we do not foresee. One potential limitation in the clonogenic assay component of our 
platform is the confounding issue of irradiated cells taking up EdU. This is based on the 
principle that apoptotic cells often have fragmented DNA that readily take up dUTP 
nucleotides via the enzyme terminal deoxynucleotidyl transferase (TDT)72. In our case, we 
have noticed highly fragmented and apoptotic cells occasionally taking up EdU, leading to 
false positives, since we would like to tailor the assay to only select for actively clonogenic 
cells. One possible solution to this is to analyze the DNA content of these cells, since it is 
likely they exist in the sub-G1 phase and can therefore be easily filtered out based on cell 
cycle phase.  
 Future studies will focus on identifying the mechanism of action for many of our 
hits. For our three HSP90 inhibitors and our four cardiac glycosides, we have data showing 
they target both the HR and ncNHEJ pathways. First, we will perform structure-activity 
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relationship studies which will reveal the particular functional groups that confer potency 
onto these compounds. To do this, we will work with chemists to create a host of derivative 
compounds whose structures differ only marginally from the index hit, and test them in our 
platform. Once we have narrowed on the most potent hits, we will perform affinity 
proteomics, in which we will use our hits as novel probes to assess for binding to various 
protein components of the DNA repair pathways. This approach can provide insight into 
key biological pathways in a complementary fashion to data obtained from conventional 
genetic knock-out or siRNA-based studies73. Finally, we hope to test these compounds in 
vivo in mice via tumor growth delay assays, which we hope will provide a critically needed 
translational component to our platform, and serve as a springboard for these compounds 
to enter clinical trials.   
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